What makes survodutide different from other dual GLP-1/glucagon agonists?

Name: Survodutide
Price: 409 USD
Availability: InStock

Survodutide uses a peptide backbone optimised for high affinity at both GLP-1 and glucagon receptors with balanced co-agonism. It has also been specifically investigated for non-alcoholic steatohepatitis (NASH) due to glucagon-mediated hepatic lipid clearance, a research application not as extensively studied with tirzepatide or semaglutide.

New

Survodutide

Dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2 data showed 19% weight reduction at the highest dose over 46 weeks.

Fat LossGH Boost

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$410

For research & laboratory use only. Not for human consumption.

Half-Life

5-7 days

Administration Route

Subcutaneous injection

GLP-1 / Glucagon Agonist

Boehringer Ingelheim dual agonist in Phase 3 for obesity

Energy Expenditure Boost

Glucagon component increases metabolic rate & thermogenesis

NASH Indication

Liver-specific glucagon action reduces hepatic fat

Effect Profile

Based on primary research mechanisms

Fat Loss

Hunger Control

Metabolic Health

Energy

Mechanism of Action

Survodutide activates both GLP-1 receptors and glucagon receptors. GLP-1 receptor activation reduces appetite and promotes glucose-dependent insulin secretion. Glucagon receptor activation stimulates hepatic fatty acid oxidation, increases resting energy expenditure through thermogenesis, and accelerates lipolysis in adipose tissue. The dual mechanism addresses both caloric intake and caloric expenditure, with the glucagon component particularly implicated in hepatic lipid clearance relevant to NASH research.